These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26528924)

  • 1. A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.
    Wang J; Zhan Q; Zhang L
    Hum Vaccin Immunother; 2016; 12(2):431-7. PubMed ID: 26528924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for psoriasis.
    Gottlieb AB
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
    Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
    J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
    Suh HY; Ahn JY; Park MY; Youn JI
    J Dermatol; 2018 Mar; 45(3):332-333. PubMed ID: 28295521
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
    Gottlieb AB; Masud S; Ramamurthi R; Abdulghani A; Romano P; Chaudhari U; Dooley LT; Fasanmade AA; Wagner CL
    J Am Acad Dermatol; 2003 Jan; 48(1):68-75. PubMed ID: 12522373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study.
    Torii H; Nakano M; Yano T; Kondo K; Nakagawa H;
    J Dermatol; 2017 May; 44(5):552-559. PubMed ID: 27882586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab for the treatment of adults with psoriasis.
    Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of infliximab in psoriatic patients over the age of 65.
    Chiricozzi A; Pavlidis A; Dattola A; Bianchi L; Chimenti MS; Fida M; Saraceno R
    Expert Opin Drug Saf; 2016 Nov; 15(11):1459-1462. PubMed ID: 27534970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced CCR9 expression levels in psoriatic skin are associated with poor clinical outcome to infliximab treatment.
    Koga A; Kajihara I; Yamada S; Makino K; Ichihara A; Aoi J; Makino T; Fukushima S; Jinnin M; Ihn H
    J Dermatol; 2016 May; 43(5):522-5. PubMed ID: 26507968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance.
    Torii H; Terui T; Matsukawa M; Takesaki K; Ohtsuki M; Nakagawa H;
    J Dermatol; 2016 Jul; 43(7):767-78. PubMed ID: 26704926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab treatment of psoriasis in supervised infusion centers: case management experience.
    Campos Muñoz L; de Unamuno Bustos B; Herranz Pinto P; El Ahmed HH; Ruiz-Villaverde R; Taberner Ferrer R
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S17-24. PubMed ID: 24777572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten years of infliximab: its role in dermatology.
    Mrowietz U; Reich K
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S10-6. PubMed ID: 19837058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports.
    Lu J; Li Y; Yu N; Chen F; Ding Y; Yi X
    J Int Med Res; 2020 Mar; 48(3):300060520912091. PubMed ID: 32216562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.